论文部分内容阅读
目的:体外观察紫杉醇及抗HER2单抗对人卵巢癌细胞株A2780增殖的抑制作用及两者联合应用时的抑制率及相互作用。方法:采用MTT法测定两者单用或合用对A2780的增殖抑制率,利用中效原理判定两药合用的效果,用流式细胞仪观察细胞凋亡及细胞周期的变化。结果:两种药单独应用时随药物剂量增加,其效应也增加,紫杉醇的中效浓度为6.98 nmol· L-1,抗HER2单抗的中效浓度为8.69μg·ml-1;两药合用时它们的中效浓度为2.92 nmol·L-1+0.49μg·ml-1。大剂量(紫杉醇>13.02 nmol·L-1,抗HER2单抗>2.17 μg·ml-1)合用时是拮抗作用(CI>1),小剂量(紫杉醇<13.02 nmol·L-1,抗HER2 单抗<2.17 μg·ml-1)合用时是协同作用(CI<1)。结论:紫杉醇联合抗HER2单抗对人卵巢癌细胞株A2780的生长有抑制作用,它们合用时大剂量是拮抗,而小剂量则为协同作用。
OBJECTIVE: To observe the inhibitory effect of paclitaxel and anti-HER2 monoclonal antibody on the proliferation of human ovarian cancer cell line A2780 in vitro and the inhibitory rate and interaction between them. Methods: MTT assay was used to determine the inhibitory effect of A2780 alone or in combination on the proliferation of A2780 cells. The effects of the two drugs were evaluated by the principle of neutralization. The apoptosis and cell cycle were observed by flow cytometry. Results: When the two drugs were applied alone, their effects increased with the increase of the dosage of paclitaxel. The median effective concentration of paclitaxel was 6.98 nmol · L-1 and the median effective concentration of anti-HER2 mAb was 8.69 μg · ml-1. When used in combination, the median effective concentration was 2.92 nmol·L-1 + 0.49 μg · ml-1. Antagonism (CI> 1), high dose (paclitaxel> 13.02 nmol·L-1, anti-HER2 mAb> 2.17 μg · ml- -1, anti-HER2 mAb <2.17 μg · ml-1) synergistically (CI <1). CONCLUSION: Paclitaxel combined with anti-HER2 monoclonal antibody can inhibit the growth of human ovarian cancer cell line A2780. When combined with paclitaxel, the anti-HER2 monoclonal antibody is antagonistic at high doses and synergistic at low doses.